Evidence map›Paper›PMID 40426230›Full record

ArticleJournal of nanobiotechnology2025

Concurrent induction of pyroptosis and immunogenic cell death by capsaicin/graphene nanocomplex for enhanced breast cancer immunotherapy.

Silu Li, Xin Jin, Yumo Zhang, Jidan Huang, Haiqiang Wang, Huan Meng, Jiulong Li, Lin Zhu

Abstract read
In one paragraph

Article in Journal of nanobiotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Silu Li *Department of Pharmacy, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, Henan, People's Republic of China.
Xin Jin *Department of Pharmacy, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, Henan, People's Republic of China.
Yumo ZhangCAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology (NCNST), Beijing, 100190, People's Republic of China.
Jidan HuangCAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology (NCNST), Beijing, 100190, People's Republic of China.
Haiqiang WangCAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology (NCNST), Beijing, 100190, People's Republic of China.
Huan MengCAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology (NCNST), Beijing, 100190, People's Republic of China. mengh@nanoctr.cn.
Jiulong LiCAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology (NCNST), Beijing, 100190, People's Republic of China. lijl@nanoctr.cn.
Lin ZhuDepartment of Pharmacy, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, Henan, People's Republic of China. zhulin66zhulin@163.com.

Funding

Basic Science Center Project of the National Natural Science Foundation of China 22388101CAS Project for Young Scientists in Basic Research YSBR-036National Key Research and Development Program of China 2022YFA1207300, 2021YFA1200902, and 2023YFC3403200National Natural Science Foundation of China 32201172 and 32271452
6 · The paper itself

Abstract

Inducing immunogenic cell death (ICD) has emerged as a promising strategy for targeting immunologically "cold" tumors. However, most current therapies focus on a single mechanism, limiting their efficacy. In this study, we propose a nano-enabled approach that synergistically activates two complementary immunogenic killing mechanisms: pyroptosis, which elicits a potent inflammatory response, and ICD, characterized by the presentation of 'eat-me' signals and tumor antigens to the immune system. Capsaicin, a naturally occurring compound, was employed to induce pyroptosis via ROS-mediated gasdermin E (GSDME) cleavage, resulting in cell membrane blebbing and subsequent cell death. To simultaneously trigger ICD, we incorporated 2D graphene oxide (GO) engineered with optimized physicochemical properties to induce robust ICD under near-infrared irradiation. Our in vitro and in vivo experiments demonstrated that the combined treatment of capsaicin and GO not only enhanced cancer cell killing but also promoted immune cell infiltration and potentiated anti-tumor immunity, leading to significant tumor suppression. Moreover, the dual-trigger mechanism of pyroptosis and ICD yielded superior anti-tumor efficacy compared to single-modality treatments while maintaining a favorable biosafety profile. These findings highlight the potential of a synergistic nano-enabled strategy for improving cancer immunotherapy.

Indexed as

Breast NeoplasmsCapsaicinGraphiteImmunogenic Cell DeathImmunotherapyPyroptosisAnimalsCell Line, TumorFemaleHumansMiceMice, Inbred BALB CReactive Oxygen SpeciesCapsaicingraphene oxideGraphiteReactive Oxygen SpeciesCancer immunotherapyCapsaicinCombination therapyImmunogenic cell deathPyroptosis

Identifiers

PMID40426230
PMCPMC12117793

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.